Brief: Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln
17/02/2025 06:05
Feb 17 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* HY LOSS ATTRIBUTABLE A$7.3 MILLION
* HY OTHER INCOME A$1.8 MILLION
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility